MedTrace Logo

Pharmacokinetics and Pharmacodynamics of TAK-875 in Subjects With Type 2 Diabetes

NCT00949091 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2010-06-11

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of multiple ascending-doses of TAK-875 in subjects with type 2 diabetes mellitus.

Conditions

  • Diabetes Mellitus, Type 2

Interventions

DRUG

TAK-875

Randomized, multiple ascending-dose sequence over 14 consecutive days to include the following: TAK-875 25 mg tablets, orally TAK-875 50 mg tablets, orally TAK-875 100 mg tablets, orally TAK-875 200 mg tablets, orally TAK-875 400 mg tablets, orally TAK-875 placebo-matching tablets, orally.

Sponsors & Collaborators

Principal Investigators

  • Medical Director Clinical Science · Takeda

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
68 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-01-31
Primary Completion
2009-07-31
Completion
2009-07-31

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00949091 on ClinicalTrials.gov